Skip to content

A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand

A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02089152
Acronym
PREMEL
Enrollment
9075
Registered
2014-03-17
Start date
2014-04-01
Completion date
2019-12-31
Last updated
2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melioidosis

Keywords

Diabetes, Melioidosis, stepped wedge trial, behaviour change, Education program

Brief summary

Study hypothesis: Prevention programme for melioidosis can reduce incidences of overall hospitalization due to infectious diseases and due to culture-confirmed melioidosis in diabetic population in northeast Thailand This study is a prospective single-blind multicentre stepped wedge cluster randomized controlled behaviour change trial in 9,000 diabetics in Ubon Ratchathani, northeast Thailand.

Detailed description

Melioidosis is an infectious disease caused by soil-dwelling Gram-negative bacilli Burkholderia pseudomallei. The disease is highly endemic in northeast Thailand. Diabetes mellitus is the major underlying risk factor for melioidosis, occurring in more than 50% of all culture-proven melioidosis patients. The annual incidence of melioidosis in diabetes in northeast Thailand is currently 244 per 100,000, and the overall case fatality rate is about 40%. The number of people dying from melioidosis is now comparable to deaths from tuberculosis, and exceeds those from malaria, diarrheal illnesses and measles combined. Melioidosis is potentially preventable since infection occurs as a direct result of exposure to B. pseudomallei in the environment. Nonetheless, most of Thai people have never heard of melioidosis, there is currently no vaccine for melioidosis, and formal prevention guideline are lacking worldwide. The investigators recently developed new guidelines for the prevention of melioidosis in Thailand; including avoidance of direct contact with soil or environmental water and use of protective gear if contact is necessary, consumption of bottled or boiled water only, and avoidance of direct contact with heavy rain and dust clouds. The investigators aim to conduct a clinical trial to determine effectiveness of the proposed prevention programme of melioidosis. The investigators also predict that the prevention programme of melioidosis will also prevent other common infectious diseases with have similar routes of infection, such as leptospirosis and acute diarrhea. The outcome of the RCT will be crucial evidence for the Ministry of Public Health (MoPH) Thailand for their consideration of policy changes for the prevention of melioidosis countrywide. The funder: Wellcome Trust. Grant reference number: 101103/Z/13/Z Result: Pubmed link: https://pubmed.ncbi.nlm.nih.gov/34170931/ PLoS NTD link: https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0009060 DOI: https://doi.org/10.1371/journal.pntd.0009060 MedRxiv: https://www.medrxiv.org/content/10.1101/2020.12.18.20248448v1

Interventions

OTHERAn educational programme for prevention of melioidosis

The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.

Sponsors

University of Oxford
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Male or female (Include pregnant women) , aged from 18 to 65 years old * Diagnosed of diabetes according to American Diabetes Association 2013 as following * Fasting plasma glucose (FPG) ≥ 126 mg/dl or * HbA1C ≥ 6.5% or * 2 hour plasma glucose (PG) ≥ 200 mg/dl during an OGTT or * Classic symptoms of hyperglycaemia with a random PG ≥ 200 mg/dl * Oriented and conversed normally * Willingness to participate in the study, and written, informed consent obtained from patient

Exclusion criteria

* Confused or unable to communicate * Diagnosed of melioidosis and has not completed oral-eradicative treatment for melioidosis

Design outcomes

Primary

MeasureTime frameDescription
Overall hospital admissions due to infectious diseasesUp to 4 yearsInfectious diseases will be determined by International Classification of Disease 10 (ICD10) defined by attending physicians.
Culture-confirmed melioidosisUp to 4 yearsCulture-confirmed melioidosis is defined as presentation with clinical features of melioidosis in association with cultures from any clinical specimen positive for Burkholderia pseudomallei.

Secondary

MeasureTime frameDescription
Overall mortalityUp to 4 yearsOverall mortality is defined as death from all causes.
Overall melioidosisUp to 4 yearsOverall melioidosis is defined as a combination of culture confirmed melioidosis and clinical melioidosis. Clinical melioidosis is defined as presentation with clinical features of melioidosis in association with cultures from all clinical specimens negative for Burkholderia pseudomallei.

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026